CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Perspectives of pediatric oncologists on referral for CAR-T therapy: a mixed methods pilot study.
Perspectives of pediatric oncologists on referral for CAR-T therapy: a mixed methods pilot study.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
近 40% 的肿瘤科医生认为,在决定是否将患者转诊接受 CAR-T 治疗时,非临床因素具有显著影响,这引发了人们对转诊过程中存在偏倚的担忧。与 CAR-T 治疗中心建立正式合作关系可能有助于解决医生在转诊方面的障碍。
在非原肿瘤科医生所在机构接受CAR-T 细胞治疗是一个复杂的多步骤过程。肿瘤科医生的转诊在这一过程中起着重要作用,但可能容易受到偏倚的影响。
曾将患者转诊接受 CAR-T 治疗的 5 家儿科医院的肿瘤科医生通过电子邮件收到调查问卷,以探讨其 CAR-T 转诊实践。生成了描述性统计,并通过多因素分析考察肿瘤科医生特征、对 CAR-T 治疗的熟悉程度与转诊实践之间的关联。我们对部分参与者进行了半结构化访谈,并使用主题分析对转录文本进行编码。
68名肿瘤科医生完成了调查;77%表示对CAR-T 疗法“非常熟悉”。西班牙裔肿瘤科医生以及每年新诊断病例数为50例或更少的机构中的肿瘤科医生更可能认为自己不太熟悉CAR-T 疗法(分别为比值比[OR]=64.3,95%置信区间[CI]=2.45至10 452.50,P=.04;OR=24.5,95% CI=3.3至317.3,P=.005)。总体而言,38%的受访者认为非临床因素(依从性、社会支持、资源、保险、语言、教育以及种族或族裔)对转诊决策有影响。西班牙裔肿瘤科医生以及已执业20年或以上的肿瘤科医生更可能认为这些因素具有显著影响(OR=14.52,95% CI=1.49至358.66,P=.04;OR=6.76,95% CI=1.18至50.5,P=.04)。9名肿瘤科医生完成了深度访谈;常见主题包括CAR-T 疗法转诊的障碍和担忧、与CAR-T 疗法中心建立关系的价值,以及CAR-T 疗法后沟通不佳。
Receipt of chimeric antigen receptor T-cell (CAR-T) therapy at an institution different from the primary oncologist's institution is a complex, multistep process. Referral by oncologists plays an important role in the process but may be susceptible to bias.
Oncologists who previously referred patients for CAR-T therapy at 5 pediatric hospitals were sent surveys by email exploring their CAR-T referral practices. Descriptive statistics were generated, and multivariate analyses examined associations among oncologist characteristics, familiarity with CAR-T therapy, and referral practices. We conducted semistructured interviews with a subset of participants and used thematic analysis to code transcripts.
Sixty-eight oncologists completed the survey; 77% expressed being "very familiar" with CAR-T therapy. Hispanic oncologists and oncologists at institutions with 50 or fewer new diagnoses per year were more likely to identify as less familiar with CAR-T therapy (odds ratio [OR] = 64.3, 95% confidence interval [CI] = 2.45 to 10 452.50, P = .04 and OR = 24.5, 95% CI = 3.3 to 317.3, P = .005, respectively). In total, 38% of respondents considered nonclinical features (compliance, social support, resources, insurance, language, education, and race or ethnicity) influential in referral decisions. Oncologists who were Hispanic and oncologists who had been practicing for 20 or more years were more likely to consider these features significantly influential (OR = 14.52, 95% CI = 1.49 to 358.66, P = .04 and OR = 6.76, 95% CI = 1.18 to 50.5, P = .04). Nine oncologists completed in-depth interviews; common themes included barriers and concerns regarding CAR-T therapy referral, the value of an established relationship with a CAR-T therapy center, and poor communication after CAR-T therapy.
Nearly 40% of oncologists consider nonclinical features significantly influential when deciding to refer patients for CAR-T therapy, raising concern for bias in the referral process. Establishing formal partnerships with CAR-T therapy centers may help address physician barriers in referral.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。